Grace Therapeutics And 2 Other US Penny Stocks Worth Watching

As the U.S. stock market reacts positively to benign inflation data, investors are exploring various opportunities across different sectors. Penny stocks, often representing smaller or newer companies, continue to attract attention due to their potential for significant returns despite the term's outdated connotations. By focusing on those with robust financials and a clear growth trajectory, investors can uncover valuable opportunities in these lesser-known stocks.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
Inter & Co (NasdaqGS:INTR)	$4.04	$1.73B	★★★★☆☆
BAB (OTCPK:BABB)	$0.893925	$6.49M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$105.8M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.76	$84.32M	★★★★★★
Pangaea Logistics Solutions (NasdaqCM:PANL)	$4.99	$236.39M	★★★★★☆
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.44	$47.69M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$0.95	$17.08M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.82	$71.95M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.50	$382.26M	★★★★☆☆

Click here to see the full list of 742 stocks from our US Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Grace Therapeutics (NasdaqCM:GRCE)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Grace Therapeutics, Inc. focuses on developing and commercializing pharmaceutical products for rare and orphan diseases in Canada, with a market cap of $38.53 million.

Operations: Grace Therapeutics, Inc. has not reported any specific revenue segments.

Market Cap: $38.53M

Grace Therapeutics, Inc., with a market cap of US$38.53 million, is pre-revenue and focuses on rare disease treatments. The company has no debt and its short-term assets of $16.1 million exceed both short-term ($2.7M) and long-term liabilities ($6.5M). Despite reducing losses by 4.7% annually over five years, it remains unprofitable with negative return on equity (-20.68%). Shareholders experienced dilution as shares outstanding increased by 7.9% last year. Recent activities include a name change from Acasti Pharma Inc., completion of patient enrollment for the Phase 3 STRIVE-ON trial, and upcoming earnings release for First-Half 2025 results.

• Get an in-depth perspective on Grace Therapeutics' performance by reading our balance sheet health report here.
• Review our growth performance report to gain insights into Grace Therapeutics' future.

X4 Pharmaceuticals (NasdaqCM:XFOR)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: X4 Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company dedicated to researching, developing, and commercializing novel therapeutics for rare diseases, with a market cap of $109.34 million.

Operations: X4 Pharmaceuticals currently does not report any revenue segments.

Market Cap: $109.34M

X4 Pharmaceuticals, with a market cap of US$109.34 million, is pre-revenue and focused on developing treatments for rare diseases. The company recently announced promising Phase 2 clinical trial results for mavorixafor, showing significant improvements in neutrophil counts and reduced need for G-CSF in chronic neutropenia patients. Despite these advancements, X4 remains unprofitable and faces financial challenges with less than a year of cash runway if current cash flow trends persist. Its short-term assets of US$143 million exceed both short-term (US$29.3M) and long-term liabilities (US$89.3M), providing some financial stability amidst ongoing volatility in its share price.

• Jump into the full analysis health report here for a deeper understanding of X4 Pharmaceuticals.
• Examine X4 Pharmaceuticals' earnings growth report to understand how analysts expect it to perform.

Koil Energy Solutions (OTCPK:KLNG)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Koil Energy Solutions, Inc. is an energy services company that offers equipment and support services to the energy and offshore industries, with a market cap of $23.54 million.

Operations: Koil Energy Solutions generates revenue primarily from its Oil Well Equipment & Services segment, which accounts for $20.80 million.

Market Cap: $23.54M

Koil Energy Solutions, with a market cap of US$23.54 million, has demonstrated strong financial performance recently, reporting third-quarter sales of US$5.22 million and net income of US$0.523 million compared to a loss last year. The company has become profitable over the past year and maintains high-quality earnings with no debt obligations, enhancing its financial stability. Despite shareholder dilution in the past year and volatile share prices, Koil's short-term assets exceed both short-term and long-term liabilities. Recent contract wins in offshore maintenance underscore its expertise in subsea services, potentially driving future growth opportunities.

• Dive into the specifics of Koil Energy Solutions here with our thorough balance sheet health report.
• Review our historical performance report to gain insights into Koil Energy Solutions' track record.

Turning Ideas Into Actions

• Take a closer look at our US Penny Stocks list of 742 companies by clicking here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com